Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Celldex Therapeutics, Inc. - Common Stock (NQ: CLDX ) 25.38 -0.27 (-1.05%) Streaming Delayed Price Updated: 10:09 AM EST, Dec 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 24,252 Open 25.51 Bid (Size) 25.36 (7) Ask (Size) 25.47 (1) Prev. Close 25.65 Today's Range 25.37 - 25.80 52wk Range 22.93 - 53.18 Shares Outstanding 66,344,236 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News What Analysts Are Saying About Celldex Therapeutics Stock December 20, 2024 Via Benzinga Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis December 19, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Performance YTD -37.19% -37.19% 1 Month -5.16% -5.16% 3 Month -22.76% -22.76% 6 Month -32.66% -32.66% 1 Year -37.56% -37.56% More News Read More Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases November 20, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock November 20, 2024 Via Benzinga Analyst Expectations For Celldex Therapeutics's Future October 28, 2024 Via Benzinga A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics September 25, 2024 Via Benzinga The Analyst Verdict: Celldex Therapeutics In The Eyes Of 7 Experts September 09, 2024 Via Benzinga Celldex Therapeutics to Present at Upcoming Investor Conferences November 11, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria October 26, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024 October 25, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire 7 Analysts Have This To Say About Celldex Therapeutics August 12, 2024 Via Benzinga Analyst Expectations For Celldex Therapeutics's Future July 16, 2024 Via Benzinga This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday September 27, 2024 Via Benzinga Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024 September 25, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024 September 16, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Therapeutics to Present at Upcoming Investor Conferences September 12, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 09, 2024 Via InvestorPlace Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update August 08, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Lattice Semiconductor Posts Weak Q2 Results, Joins Symbotic, Woodward And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session July 30, 2024 Via Benzinga Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session July 30, 2024 Via Benzinga Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket July 30, 2024 Via Benzinga Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria July 29, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio? July 28, 2024 Via Benzinga Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria July 16, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Therapeutics to Present at Jefferies Healthcare Conference June 04, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
